AZD1390 clinical trials
Also written AZD1390.
How each study uses AZD1390 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD1390 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD1390
- 7
Studies by the year they started
9 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 6
AstraZeneca (3) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Nader Sanai (1) · Global Coalition for Adaptive Research (1) · University of Leeds (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · Tinostamustine (1) · Olaparib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses AZD1390 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as AZD1390
- Human ADME Study of [14C]-AZD1390Not yet recruitingPhase 1AstraZenecaNCT07643870Written as AZD1390
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104Written as AZD1390
- A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerCompletedPhase 1AstraZenecaNCT03423628Written as AZD1390
- Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine GliomaActive, not recruitingPhase 1Children's Oncology GroupNCT06894979Written as ATM Kinase Inhibitor AZD1390
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor CancerActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05678010Written as AZD1390
- AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma PatientsActive, not recruitingEarly Phase 1Nader SanaiNCT05182905Written as AZD1390
- Sarcomas and DDR-Inhibition; a Combined Modality StudyTerminatedPhase 1The Netherlands Cancer InstituteNCT05116254Written as AZD1390 + radiotherapy
- AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy VolunteersCompletedPhase 1AstraZenecaNCT03215381Written as [11C]AZD1390
Codes
What other systems call AZD1390 · ClinicalTrials.gg INT002042
- MeSH (NLM) C000729307AZD1390One source ClinicalTrials.gov
- NCI Thesaurus C150167ATM Kinase Inhibitor AZD1390One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729307 | AZD1390 | One source ClinicalTrials.gov |
| NCI Thesaurus | C150167 | ATM Kinase Inhibitor AZD1390 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.